CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance

Blood

Volumn 113, Issue 15, 2009, Pages 3475-3484

  Kurtz, Josef ^a   Raval, Forum ^a   Vallot, Casey ^a   Der, Jayden ^a,b   Sykes, Megan ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b EMMANUEL COLLEGE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; B7 ANTIGEN; CD28 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL INTERACTION; CELL POPULATION; CHIMERA; CONTROLLED STUDY; DONOR; HEMATOPOIESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 65349134818     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-133736     Document Type: Article

References (75)

1. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allo-geneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation. 1995;59: 256-262.
2. Huang CA, Fuchimoto Y, Scheier-Dolberg R, Murphy MC, Neville DM Jr, Sachs DH. Stable mixed chimerism and tolerance using a nonmy- eloablative preparative regimen in a large-animal model. J Clin Invest. 2000;105:173-181.
3. FudabaY, SpitzerTR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplanta-tion: in vivo and in vitro analyses. Am J Trans-plant. 2006;6:2121-2133.
4. Sykes M. Mixed chimerism and transplant tolerance. Immunity. 2001;14:417-424.
5. Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central Tcell tolerance. J Exp Med. 1998;187:2037-2044.
6. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory block-ade induces macrochimerism and tolerance with out cytoreductive host treatment. Nat Med. 2000; 6:464-469.
7. Seung E, Iwakoshi N, Woda BA, et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 anti-body: absence of graft-versus-host disease, in-duction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood. 2000;95:2175-2182.
8. Seung E, Mordes JP, Rossini AA, Greiner DL. Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J Clin Invest. 2003; 112:795-808.
9. Durham MM, Bingaman AW, Adams AB, et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chi- merism and donor-specific tolerance without cy- toreductive conditioning. J Immunol. 2000;165:1-4.
10. Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol. 2002;14:592-600.
11. Ito H, Kurtz J, Shaffer J, Sykes M. CD4T cell- mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is depen-ent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this path-way. J Immunol. 2001;166:2970-2981.
12. Kurtz J, Shaffer J, Lie A, Anosova N, Benichou G, Sykes M. Mechanisms of early peripheral CD4 T cell tolerance induction by anti-CD154 monoclo-nal antibody and allogeneic bone marrow trans-plantation: evidence for anergy and deletion, but not regulatory cells. Blood. 2004;103:4336-4343.
13. Adams AB, Durham MM, Kean L, et al. Costimu- lation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce trans-plantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppres- sion. J Immunol. 2001;167:1103-1111.
14. Kurtz J, Wekerle T, Sykes M. Tolerance in mixed chimerism: a role for regulatory cells? Trends Im-munol. 2004;25:518-523.
15. Domenig C, Sanchez-Fueyo A, Kurtz J, et al. Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a non- lymphoablative irradiation-free protocol. J Immu-nol. 2005;175:51-60.
16. Bigenzahn S, Blaha P, Koporc Z, et al. The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am J Transplant. 2005;5:1237-1247.
17. Kurtz J, Ito H, WekerleT, Shaffer J, Sykes M. Mechanisms involved in the establishment of tol-erance through costimulatory blockade and BMT: lack of requirement for CD40L-mediated signal--ing for tolerance or deletion of donor-reactive CD4+ cells. Am J Transplant. 2001;1:339-349.
18. Fehr T, Takeuchi Y, Kurtz J, Wekerle T, Sykes M. Early regulation of CD8 Tcell alloreactivity by CD4 + CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for sustained regulation. Eur J Immunol. 2005;35:2679-2690.
19. 19.Takeuchi Y, Ito H, Kurtz J, Wekerle T, Ho L, Sykes M. Earlier low-dose TBI or DST overcomes CD8+ T-cell-mediated alloresistance to alloge-neic marrow in recipients of anti-CD40L. Am J Transplant. 2004;4:31-40.
20. Greenwald RJ, Freeman GJ, SharpeAH.The B7 family revisited. Annu Rev Immunol. 2005;23:515-548.
21. Yu XZ, Albert MH, Martin PJ, Anasetti C. CD28 ligation induces transplantation tolerance byIFN- gamma-dependent depletion of T cells that recog-nize alloantigens. J Clin Invest. 2004;113:1624-1630.
22. Tang Q, Smith JA, Szot GL, et al. CD28/B7 regu-lation of anti-CD3-mediated immunosuppression invivo. J Immunol. 2003;170:1510-1516.
23. Salomon B, Bluestone JA. Complexities of CD28/ B7: CTLA-4 costimulatory pathways in autoimmu- nity and transplantation. Annu Rev Immunol.2001;19:225- 252.
24. Sykes M, Romick ML, Hoyles KA, Sachs DH. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus- host disease mortality and permits alloengraft- ment. J Exp Med. 1990;171:645-658.
25. Tomita Y, Sachs DH, Khan A, Sykes M. Additional monoclonal antibody (mAB) injections can re-place thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irra-diation. Transplantation. 1996;61:469-477.
26. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multior- gan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541-547.
27. Mandelbrot DA, McAdam AJ, Sharpe AH. B7-1 or 27-2 is required to produce the lymphoprolifera- tive phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med. 1999;189:435-440.
28. Nikolic B, Khan A, Sykes M. Induction of toler-ance by mixed chimerism with nonmyeloblative host conditioning: the importance of overcoming intrathymic alloresistance. Biol Blood Marrow Transplant. 2001;7:144-153.
29. Krummel MF, Sullivan TJ, Allison JP. Superanti- gen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expan-sion in vitro and in vivo. Int Immunol. 1996;8:519-523.
30. Salomon B, Lenschow DJ, Rhee L, et al. B7/ CD28 costimulation is essential for the homeosta- sis of the CD4+CD25+ immunoregulatoryT cells that control autoimmune diabetes. Immunity.2000;12:431-440.
31. Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory Tcells. J Immunol.2003;171:3348- 3352.
32. Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatoryT-cell biology. Immunol Rev. 2006;212:131-148.
33. Lohr J, Knoechel B, Jiang S, Sharpe AH, Abbas AK. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol. 2003;4:664-669.
34. Zheng X, Gao JX, Chang X, et al. B7-CD28 inter-action promotes proliferation and survival but suppresses differentiation of CD4-CD8- Tcells in the thymus. J Immunol. 2004;173:2253-2261.
35. Williams JA, Hathcock KS, Klug D, et al. Regu-lated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimula- tion can bypass the pre-TCR checkpoint. J Immu-nol. 2005;175:4199-4207.
36. Lucas B, Germain RN. Opening a windowon thy- mic positive selection: developmental changes in the influence of cosignaling by integrins and CD28 on selection events induced byTCR en-gagement. J Immunol. 2000;165:1889-1895.
37. Noel PJ, Alegre ML, Reiner SL, Thompson CB. Impaired negative selection in CD28-deficient mice. Cell Immunol. 1998;187:131-138.
38. Vidric M, Suh WK, Dianzani U, MakTW, Watts TH. Cooperation between 4-1BB and ICOS in the immune response to influenza virus revealed by studies of CD28/ICOS-deficient mice. J Immunol.2005;175:7288-7296.
39. McNerney ME, Lee KM, Zhou P, et al. Role of natural killer cell subsets in cardiac allograft rejection. Am J Transplant. 2006;6:505-513.
40. Szot GL, Zhou P, Rulifson I, et al. Different mechanisms of cardiac allograft rejection in wild- type and CD28-deficient mice. Am J Transplant.2001;1:38-46.
41. Perkins D, Wang Z, Donovan C, et al. Regulation of CTLA-4 expression during T cell activation.J Immunol. 1996;156:4154-4159.
42. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol.1999;162:5813-5820.
43. Bachmann MF, Kohler G, Ecabert B, MakTW, Kopf M. Cutting edge: lymphoproliferative dis-ease in the absence of CTLA-4 is not Tcell au-tonomous. J Immunol. 1999;163:1128-1131.
44. Bachmann MF, Gallimore A, Jones E, Ecabert B, Acha-Orbea H, Kopf M. Normal pathogen-spe-cific immune responses mounted by CTLA-4-defi- cient T cells: a paradigm reconsidered. Eur J Im-munol. 2001;31:450-458.
45. Read S, Greenwald R, Izcue A, et al. Blockade of CTLA-4 on CD4+CD25+ regulatoryT cells abrogates their function in vivo. J Immunol. 2006;177:4376-4383.
46. Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA. Inhibition of T cell activation and autoimmune diabetes using a B cell surface- linked CTLA-4 agonist. J Clin Invest. 2006;116:2252-2261.
47. Greenwald RJ, Oosterwegel MA, van der Woude D, et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immu-nol. 2002;32:366-373.
48. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-465.
49. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tu-mor immunotherapy. Nat Immunol. 2002;3:611-618.
50. Martin M, Schneider H, AzouzA, Rudd CE. Cyto-toxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function. J Exp Med. 2001;194:1675-1681.
51. Darlington PJ, Baroja ML, Chau TA, et al. Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immu- nological synapse under conditions of inhibition of Tcell activation. J Exp Med. 2002;195:1337-1347.
52. Chikuma S, Imboden JB, Bluestone JA. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic Tlymphocyte-associated antigen 4. J Exp Med. 2003;197:129-135.
53. Wells AD, Walsh MC, Bluestone JA, Turka LA. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest. 2001;108:895-903.
54. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CTLA-4 regulates induction of anergy in vivo. Immunity. 2001;14:145-155.
55. Mirshahidi S, Huang CT, Sadegh-Nasseri S. An- ergy in peripheral memory CD4(+) T cells in-duced by low avidity engagement of T cell receptor. J Exp Med. 2001;194:719-731.
56. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engage-ment. Immunity. 1997;6:411-417.
57. Vanasek TL, Khoruts A, Zell T, Mueller DL. An-tagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal an- ergy: enhanced cell cycle progression promotes recall antigen responsiveness. J Immunol. 2001;167:5636-5644.
58. Chen W, Jin W, Wahl SM. Engagement of cyto-toxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med. 1998;188:1849-1857.
59. Nakamura K, Kitani A, Strober W. Cell contact- dependent immunosuppression by CD4(+)CD25(+) regulatory Tcells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194:629-644.
60. Schneider H, Mandelbrot DA, Greenwald RJ, et al. Cutting edge: CTLA-4 (CD152) differentially regulates mitogen-activated protein kinases (ex-tracellular signal-regulated kinase and c-Jun N-terminal kinase) in CD4+ T cells from receptor/ ligand-deficient mice. J Immunol. 2002;169:3475-3479.
61. Gribben JG, Freeman GJ, Boussiotis VA, et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA. 1995; 92:811-815.
62. Scheipers P, Reiser H. Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci U S A. 1998;95:10083-10088.
63. Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science.2006;313:1972-1975.
64. Kurtz J, Lie A, Griffith M, et al. Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. Am J Transplant. 2003;3:804-816.
65. Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL. Treatment of allo- graft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of allo- reactive CD8+ T cells and prolonged graft sur-vival in a CTLA4-dependent manner. J Immunol.2000;164:512- 521.
66. Coenen JJ, Koenen HJ, van Rijssen E, Boon L, Joosten I, Hilbrands LB. CTLA-4 engagement and regulatory CD4+CD25+ T cells indepen-dently control CD8+-mediated responses under costimulation blockade. J Immunol. 2006;176:5240-5246.
67. Taylor PA, Lees CJ, Fournier S, Allison JP, Sharpe AH, Blazar BR. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation viaT-T interactions [corrections]. J Immunol. 2004;172:34-39.
68. Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells pre-vents autoimmune disease. Proc Natl Acad Sci U S A. 2004;101:10398-10403.
69. Butte MJ, Keir ME, PhamduyTB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 inter-acts specifically with the B7-1 costimulatory mole-cule to inhibit T cell responses. Immunity. 2007; 27:111-122.
70. Rulifson IC, Szot GL, Palmer E, Bluestone JA. Inability to induce tolerance through direct anti-gen presentation. Am J Transplant. 2002;2:510-519.
71. Quezada SA, Fuller B, Jarvinen LZ, et al. Mecha-nisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation. Blood. 2003;102:1920-1926.
72. Kishimoto K, Yuan X, Auchincloss H Jr, Sharpe AH, Mandelbrot DA, Sayegh MH. Mechanism of action of donor-specific transfusion in inducing tolerance: role of donor MHC molecules, donor co-stimulatory molecules, and indirect antigen presentation. J Am Soc Nephrol. 2004;15:2423- 2428.
73. FehrT, Haspot F, Mollov J, Chittenden M, Hogan T, Sykes M. Alloreactive CD8T cell tolerance requires recipient B cells, dendritic cells, and MHC class II. J Immunol. 2008;181:165-173.
74. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces anti-gen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987;165:302-319.
75. Smyth LA, Herrera OB, Golshayan D, Lombardi G, Lechler RI. A novel pathway of antigen presen-tation by dendritic and endothelial cells: implica-tions for allorecognition and infectious diseases. Transplantation. 2006;82:S15-S18.